[1]
|
F. Marmol, “Lithium: Bipolar Disorder and Neurodegenerative Diseases Possible Cellular Mechanisms of the Therapeutic Effects of Lithium,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol. 32, No. 8, 2008, pp. 1761-1771. doi:10.1016/j.pnpbp.2008.08.012
|
[2]
|
G. E. Simon, “Social and Economic Burden of Mood Disorders,” Biological Psychiatry, Vol. 54, No. 3, 2003, pp. 208-215. doi:10.1016/S0006-3223(03)00420-7
|
[3]
|
H. U. Wittchen, S. Muhlig and L. Pezawas, “Natural Course and Burden of Bipolar Disorders,” The International Journal of Neuropsychopharmacology, Vol. 6, No. 2, 2003, pp. 145-154. doi:10.1017/S146114570300333X
|
[4]
|
S. W. Woods, “The Economic Burden of Bipolar Disease,” Journal of Clinical Psychiatry, Vol. 61, 2000, pp. 38-41.
|
[5]
|
A. Ezzaher, D. Haj Mouhamed, A. Mechri, F. Neffati, W. Douki, L. Gaha and M. F. Najjar, “Association between Bipolar I Disorder and the L55M and Q192R Polymorphisms of the Paraoxonase 1 (PON1) Gene,” Journal of Affective Disorders, Vol. 139, No. 1, 2012, pp. 12-17.
doi:10.1016/j.jad.2011.06.029
|
[6]
|
D. A. Revicki, L. S. Matza, E. Flood and A. Lloyd, “Bipolar Disorder and Health-Related Quality of Life: Review of Burden of Disease and Clinical Trials,” Pharmacoeconomics, Vol. 23, 2005, pp. 583-594.
doi:10.2165/00019053-200523060-00005
|
[7]
|
R. J. Wyatt and I. Henter, “An Economic Evaluation of Manicdepressive Illness: 1991,” Social Psychiatry and Psychiatric Epidemiology, Vol. 30, No. 5, 1995, pp. 213-219.
|
[8]
|
M. De Hert, C. U. Correll, J. Bobes, M. Cetkovich-Bakmas, D. Cohen, I. Asai J. Detraux, S. Gautam, H. J. Moller, D. M. Ndetei, J. W. Newcomer, R. Uwakwe and S. Leucht, “Physical Illness in Patients with Severe Mental Disorders. I. Prevalence, Impact of Medications and Disparities in Health Care,” World Psychiatry, Vol. 10, 2011, pp. 52-77.
|
[9]
|
D. E. Casey, “Metabolic Issues and Cardiovascular Disease in Patients with Psychiatric Disorders,” American Journal of Medicine, Vol. 118, 2005, pp. 15-22.
|
[10]
|
S. Malhotra and S. L. McElroy, “Medical Management of Obesity Associated with Mental Disorders,” Journal of Clinical Psychiatry, Vol. 63, 2002, pp. 24-32.
|
[11]
|
American Psychiatric Association, “Diagnostic and Statistical Manual of Mental Disorders,” 4 Edition, American Psychiatric Association, Washington DC, 2004.
|
[12]
|
World Health Organization, “Obesity: Preventing and Managing the Global Epidemic (publication WHO/NUT/ NCD/98.1),” WHO, Geneva, 1997.
|
[13]
|
H. Pijil and A. E. Meinders, “Bodyweight Change as an Adverse Effect of Drug Treatment: Mechanisms and Management,” Drug Safety, Vol. 14, 1996, pp. 329-342.
doi:10.2165/00002018-199614050-00005
|
[14]
|
J. L. Elmslie, J. T. Silverstone, J. L. Mann, S. M. Williams and S. E. Romans, “Prevalence of Overweight and Obesity in Bipolar Patients,” Journal of Clinical Psychiatry, Vol. 61, 2000, pp. 179-184.
doi:10.4088/JCP.v61n0306
|
[15]
|
A. Fagiolini, E. Frank, P. R. Houck, A. G. Mallinger, H. A. Swartz, D. J. Buysse, H. Ombao and D. J. Kupfer, “Prevalence of Obesity and Weight Change during Treatment in Patients with Bipolar I Disorder,” Journal of Clinical Psychiatry, Vol. 63, 2002, pp. 528-533.
doi:10.4088/JCP.v63n0611
|
[16]
|
S. L. McElroy, R. Kotwal, S. Malhotra, E. B. Nelson, P. E. Keck and C. B. Nemeroff, “Are Mood Disorders and Obesity Related? A Review for the Mental Health Professional,” Journal of Clinical Psychiatry, Vol. 65, 2004, pp. 634-651. doi:10.4088/JCP.v65n0507
|
[17]
|
F. G. Haddad, H. Brax, E. Zein and T. Abou el Hessen, “L’obésité et les Pathologies Associées dans un Centre de Soins au Liban,” Journal Medical Libanais, Vol. 54, 2006, pp. 152-155.
|
[18]
|
A. Fagiolini, D. J. Kupfer, P. R. Houck, D. M. Novick and E. Frank, “Obesity as a Correlate of Outcome in Patients with Bipolar I Disorder,” American Journal of Medicine, Vol. 160, 2003, pp. 112-117.
|
[19]
|
M. P. Garcia-Portilla, P. A. Saiz, M. T. Bascaran, S. Martinez, A. Benabarre, P. Sierra, P. Torres, J. M. Montes, M. Bousono and J. Bobes, “Cardiovascular Risk in Patients with Bipolar Disorder,” Journal of Affective Disorders, Vol. 115, No. 3, 2009, pp. 1-7.
doi:10.1016/j.jad.2008.09.008
|
[20]
|
A. Ezzaher, D. Haj Mouhamed, A. Mechri, F. Neffati, W. Douki, L. Gaha and M. F. Najjar, “Cardiovascular Risk in Tunisian Patients with Bipolar I Disorder,” DyslipidemiaFrom Prevention to Treatment, Rijeka, 2012.
|
[21]
|
J. Pinkney, “Implications of Obesity for Diabetes and Coronary Heart Disease in Clinical Practice,” Britsh Journal of Diabetes and Vascular Disease, Vol. 1, No. 2, 2001, pp. 103-106. doi:10.1177/14746514010010020701
|
[22]
|
P. W. Wang, G. S. Sachs, C. A. Zarate, L. B. Marangell, J. R. Calabrese, J. F. Goldberg, K. Sagduyu, S. Miyahara and T. A. Ketter, “Overweight and Obesity in Bipolar Disorders,” Journal of Psychiatric Research, Vol. 40, No. 8, 2006, pp. 762-764.
doi:10.1016/j.jpsychires.2006.01.007
|
[23]
|
R. S. McIntyre, J. Z. Konarski, K. Wilkins, J. K. Soczynska and S. H. Kennedy, “Obesity in Bipolar Disorder and Major Depressive Disorder: Results from a National Community Health Survey on Mental Health and Well-Being,” Canadian Journal of Psychiatry, Vol. 51, No. 5, 2006, pp. 274-280.
|
[24]
|
P. J. R. Teixeira and F. L. Rocha, “The Prevalence of Metabolic Syndrome among Psychiatric Inpatients in Brazil,” Brazilian Journal of Psychiatry, Vol. 29, No. 4, 2007, pp. 330-336.
|
[25]
|
A. Ezzaher, D. Haj Mouhamed, A. Mechri, F. Neffati, W. Douki, L. Gaha and M. F. Najjar, “Lower Paraoxonase 1 Activity in Tunisian Bipolar I Patients,” Annals of General Psychiatry, Vol. 9, 2010, p. 36.
doi:10.1186/1744-859X-9-36
|
[26]
|
G. Maina, V. Salvi , A. Vitalucci, V. D’Ambrosio and F. Bogetto, “Prevalence and Correlates of Overweight in Drug-Naive Patients with Bipolar Disorder,” Journal of Affective Disorders, Vol. 110, No. 1-2, 2008, pp. 149-155. doi:10.1016/j.jad.2007.12.233
|
[27]
|
A. J. Stunkard, M. S. Faith and K. C. Allison, “Depression and Obesity,” Biological Psychiatry, Vol. 54, No. 3, 2003, pp. 330-337. doi:10.1016/S0006-3223(03)00608-5
|
[28]
|
G. Cheymol, “Effects of Obesity on Pharmacokinetics Implications for Drug Therapy,” Clinical Pharmacokinetics, Vol. 39, No. 3, 2000, pp. 215-231.
doi:10.2165/00003088-200039030-00004
|
[29]
|
D. T. Plante and J. W. Winkelman, “Sleep Disturbance in Bipolar Disorder: Therapeutic Implications,” American Journal of Psychiatry, Vol. 165, No. 7, 2008, pp. 830-843.
doi:10.1176/appi.ajp.2008.08010077
|
[30]
|
A. Ezzaher, D. Haj Mouhamed, A. Mechri, F. Neffati, W. Douki, L. Gaha and M. F. Najjar, “Obesity and Dyslipidemia in Tunisian Bipolar Subjects,” Annales de Biologie Clinique, Vol. 68, 2010, pp. 277-284.
|
[31]
|
D. C. Lagace, R. S. Mcleod and M. W. Nachtigal, “Valproic Acid Inhibits Leptin Secretion and Reducesleptin Messenger Ribonucleic Acid Levels in Adipocytes,” Endocrinology, Vol. 145, No. 12, 2004, p. 5493.
doi:10.1210/en.2004-0877
|